Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
August 5, 2025

Linc01232 regulates mir-516a-5p/bcl9 axis to promote triple-negative breast cancer progression

View Full Paper
Ask AI
Bookmark
Share

Authors

WLWei LiuYNYunfeng NiuJAJie An

Discussion

Loading...

Member takes

Overview

Research demonstrates LINC01232 enhances migration and invasion in triple-negative breast cancer, indicating its role in the miR-516a-5p/BCL9 axis.

Key Points

  • LINC01232 is overexpressed in triple-negative breast cancer tissues compared to normal tissues.
  • Silencing LINC01232 significantly reduces cell proliferation, migration, and invasion in breast cancer cells.
  • LINC01232 competes with miR-516a-5p, decreasing its expression and increasing BCL9 levels.
  • These findings highlight LINC01232 as a potential therapeutic target in managing TNBC progression.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/689a0f93e6551bb0af8d12afhttps://doi.org/10.21203/rs.3.rs-7167048/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting LINC02544/miR-497-5p/CAPRIN1 axis via exosome-based siRNA to overcome immunotherapy resistance in triple-negative breast cancer2025
  2. 2The Good, the Bad, or Both? Unveiling the Molecular Functions of LINC01133 in Tumors2025
  3. 3LNC01089-LINC00963/miR-1244-5p/IGF1 ceRNA Axis Regulate FOXO Signaling Pathway in Breast Cancer Patients: A Biomarker Discovery Investigation2025
  4. 4The Emerging Landscape of LINC01123 in Cancer: Roles, Mechanisms, and Clinical Significance2025
  5. 5Robust CRISPR Screens Identify TPL1 as a Novel Long Noncoding RNA Driving Triple-Negative Breast Cancer Hallmarks2025